跳至主要内容
临床试验/JPRN-jRCT2080223982
JPRN-jRCT2080223982已完成2 期

A phase II study of Ad-SGE-REIC

Kyorin Pharmaceutical Co.,LTD0 个研究点目标入组 15 人开始时间: 2018年7月19日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
15

研究概览

简要总结

The study was discontinued during the study due to below the pre-defined threshold of median PFS for judgement of the efficacy. While there was one subject with a partial response (PR) in the best overall response, there was no overall trend toward tumor reduction with the product. Safety was generally within the expected safety profile.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Key inclusion criteria
  • Pathologically confirmed malignant pleural mesothelioma which isunresectable
  • Patients with one or more measurable disease
  • Patients who have adequate main organs function
  • Patients who signed written informed consent

排除标准

  • Key exclusion criteria
  • Patients with simultaneous tumor and/or metachronaus tumor (excluding patients with them whose disease-free interval is over 2 years)
  • Active infections
  • Symptomatic brain metastasis requiring treatment
  • Pulmonary fibrosis or interstitial pneumonia
  • Cardiac effusion requiring treatment
  • Comorbidities requiring systemic corticosteroid or an immunosuppressants

研究者

相似试验